Skip to main content
. 2020 Jan 13;10(1):5. doi: 10.1038/s41408-019-0271-z

Table 1.

Summary of pathologic and cytogenetic features of cases with MYC amplification.

Final Classification n = 42a WHO DHL (n = 12) DLBCL (n = 22) HGBCL, NOS (n = 3) Plasmablastic (n = 2) Unknown Cytologyb (n = 3)
High-grade morphology 1/11 (9%) 0/22 (0%) 3/3 (100%) NA Unknown
GCB by Hans 8/9 (89%) 15/18 (83%) 2/2 (100%) NA Unknown
Double expresser 5/7 (71%) 6/16 (38%) 2/2 (100%) 1/1 (100%) 1/1 (100%)
MYC-non-IGH 10/12 (83%) 7/22 (32%) 1/3 (33%) 2/2 (100%) 1/3 (33%)
MYC-IGH 2/12 (17%) 2/22 (9%) 0/3 (0%) 0/2 (0%) 0/3 (0%)
MYC-any R; NO BCL2 or BCL6-R NA 9/22 (41%) 1/3 (33%) 2/2 (2%) 1/3 (33%)
MYC-any R; BCL2-R or BCL6-R present 12/12 (100%) NA NA 0/2 (0%) NA
NO MYC-R; BCL2-R and/or BCL6-R present NA 5/21 (24%) 0/3 (0%) NA 2/2 (100%)

Cases are classified by final WHO pathologic classification based on morphologic, immunohistochemical, and cytogenetic features

NA Not applicable

GCB Germinal center B cell

BCL2-R: BCL2 rearranged

MYC-any R = MYC sep = MYC any rearrangement

aTwo cases are not included in the table as complete BCL2 or BCL6 FISH was not available for review precluding final classification as either DLBCL or HGBL NOS

bUnknown Cytology: cases in which H&E was not available for morphologic review, thus cannot be classified as either DLBCL or HGBL NOS